Roth Positive on Spectrum Pharma (SPPI) Following CE-Melphalan NDA Filing (LGND)
Tweet Send to a Friend
Roth Capital affirms Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) at Buy with a price target of $15 following news the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
